Salubris rose 1.45% as the company's self-developed phase III clinical trial of a new drug for hypertension reached the primary endpoint target

At 11:42 on January 12, Salubris rose 1.
45%, quoted 35.
61 yuan, with a turnover of 86.
08 million, a turnover rate of 0.
22%, and a price-to-earnings (TTM) of 58.
27
.
On the news, the company announced on the evening of January 11 that recently, the company's self-developed S086 tablets for the treatment of mild and moderate primary hypertension indications phase III.
clinical trial has been completed blinding and statistical analysis preliminary results show that the primary endpoint target
has been reached.
The preliminary statistical analysis results after this unblinding showed that S086 tablets had significant antihypertensive efficacy, good overall safety and dose-dependence
.
According to reports, S086 is a double inhibitor of angiotensin II receptor-neprilysin (ARNi), with the target indications of hypertension and chronic heart failure, both of which are in phase III clinical trials
.
The drug is independently innovated and developed by Salubris and is the second ARNi class small molecule chemical drug in the world to enter the clinic, with low drug interaction risk, good safety and protective effect on target organs such as heart and kidney
.
The company said that after the successful launch of the product, it will further enrich the company's innovative product pipeline in the cardiovascular field, meet unmet clinical needs, and enhance the company's comprehensive competitiveness
in the field of chronic diseases.
According to the data, Salubris is a domestic cardiovascular chronic disease drug enterprise, in recent years, the company is steadily moving forward in the direction of high-end innovative pharmaceutical enterprises by continuing to increase investment in innovative drug research and development, at present, the company has completed the layout of the cardiovascular field as the core, to anti-tumor, hypoglycemic, orthopedic, anti-infection and other focus areas to expand and extend, innovative product echelon has gradually formed
.
The number of chronic disease patients in China is huge, about 300 million, of which hypertension accounts for 267 million
.
With the aging of China's population and the change of lifestyle, the number of patients with chronic diseases in China will continue to grow and show a younger trend, and the market demand for chronic disease drugs in the vast number of patients will continue to grow
.
According to the "2022 Chronic Disease Retail Market Analysis" report released by Minai.
com, the total sales of the five major chronic disease drugs of antihypertensive drugs, lipid-lowering drugs, hypoglycemic drugs, antithrombotic drugs, and other cardiovascular and cerebrovascular drugs reached 322.
7 billion yuan in China's public medical institutions, China's urban physical pharmacies and online pharmacy terminals in 2021, a year-on-year increase of 4.
2%.

According to the overall market size of 2 trillion yuan of drugs in China, the overall market for chronic diseases will exceed 400 billion yuan
in 2022.
It is understood that chronic disease drugs with the cardiovascular field as the core have always been the focus of Salubris efforts, and Salubris has a rich pipeline in the field of chronic disease drugs, covering cardiovascular, hypoglycemic, orthopedic and anti-tumor, etc.
, and its central cerebrovascular accounts for the majority
.
Data show that as of the first half of 2022 alone, among the new drugs under research in Salubris alone, there are 7 new drugs in cardiovascular and related fields, including AL0107, SAL056, SAL0108, SALO15, etc
.
In addition to S086 tablets, the progress of cardiovascular drugs under research by Salubris has been continuously
reported since the second half of 2022.
For example, on November 4, 2022, Salubris announced that SAL0107 (alisartan amlodipine tablets) was accepted as a new drug Class 2.
3, and at present, only one Salubris has reported production of this product
.
According to data from Minai.
com, the sales scale of terminal cardiovascular and cerebrovascular system drugs in China's public medical institutions has exceeded 100 billion yuan in 2021, with a year-on-year increase of 6.
24%
in the first half of 2022.
After the launch, the product will form a strategic synergy with Salubris Superior Nassellation's Class 1.
1 antihypertensive drug Salubris (alisartan cilexetil tablets) to further enrich the company's innovative product pipeline in the cardiovascular field and cover a wider range
of hypertensive patients.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.